<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty three Zimbabwean African patients who satisfied the French-American-British(FAB) diagnostic criteria for the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) at Godfrey Huggins School of Medicine, University of Zimbabwe, between July 1985 and June 1987 are presented </plain></SENT>
<SENT sid="1" pm="."><plain>The disorders appear not to behave differently from those reported in Caucasian populations with regard to clinical and haematological features </plain></SENT>
<SENT sid="2" pm="."><plain>Refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) occurred in 12 (52.2%) patients; refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) in 4 (17.4%) patients; refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 2 (8.7%) patients; refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 3 (13.0%) patients; while <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) was observed in 2 (8.7%) patients </plain></SENT>
<SENT sid="3" pm="."><plain>In 19 cases, the disease was primary and in 4 prior exposure to myelotoxic agents resulted in <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical significance of recognising the disorders is briefly high-lighted together with our current treatment protocol </plain></SENT>
</text></document>